Edwards (Shanghai) Medical Supplies Co., Ltd.

Edwards Lifesciences (hereinafter referred to as "Edwards") is a global leader in medical innovation in the field of structural heart disease. Founded in 1958 in Irvine, Orange County, California, USA, Edwards has been dedicated to transforming heart valve technology since introducing the first commercially available artificial heart valve in 1960. Edwards has consistently driven long-term advancements in the treatment of heart valve disease. Over more than 60 years, the company has maintained a leading position in the field of heart valve therapy.

Adhering to the corporate value of "Patients First," Edwards collaborates closely with the world's top clinicians and research scholars to continuously fill medical gaps, jointly improving patient outcomes and quality of life. Currently, Edwards employs approximately 16,000 people globally, with operations in over 100 countries and regions.

In 2001, Edwards officially entered the Chinese market. Guided by the principle of "Wholehearted Care, Leading Innovation in China," Edwards China accelerates the launch of new products while actively expanding patient access to innovative diagnostic and therapeutic solutions, enabling more patients to benefit from high-quality, high-tech innovative products. Edwards currently operates two major business segments in China: Surgical Structural Heart Valve Therapies (SURG) and Transcatheter Aortic Valve Replacement Therapies (THV). In the future, Edwards will continue to expand its business in Transcatheter Mitral and Tricuspid Therapies (TMTT).

To date, Edwards has introduced over 20 innovative products in China, with business coverage across 31 provinces, municipalities, autonomous regions, and municipalities directly under the central government. It is currently conducting five clinical trials, has trained over 20,000 Chinese clinicians cumulatively, and more than 1.5 million Chinese patients have benefited from Edwards' innovative products and technologies. The company has offices in Shanghai, Beijing, Guangzhou, and the Hong Kong Special Administrative Region, with Shanghai serving as the China headquarters. Over 380 employees at Edwards China strive to contribute to a healthier future for Chinese patients.

Furthermore, Edwards actively partners with stakeholders from government, industry, academia, research, and medicine to jointly advance the development of China's health sector. Edwards has established clinical collaborations with more than ten hospitals, including Fuwai Hospital of the Chinese Academy of Medical Sciences and West China Hospital of Sichuan University, to promote and improve the level of cardiovascular disease treatment in China. It also collaborates with industry organizations such as the Chinese Medical Association, the Chinese Health Economics Association, and the Chinese Medical Doctor Association to support disease education and clinical training, further enhancing the clinical soft power of Chinese physicians. At the same time, Edwards continues to expand local innovation cooperation models and promote the distribution of quality medical resources to benefit more Chinese patients.

While continuously developing its business, Edwards also actively gives back to society as a responsible corporate citizen. The Edwards Every Heartbeat Matters public welfare program aims to help educate, screen, and treat patients with structural heart disease worldwide who lack access to medical services. To date, approximately 15,000 Chinese patients have benefited from this program.

Edwards improves patients' quality of life through breakthrough medical technologies, wins trust through excellent quality and integrity, provides a platform for employee growth and development through an inclusive corporate culture, and dedicates itself to public welfare with full enthusiasm, serving the communities where it operates, and striving to contribute to the early realization of the "Healthy China 2030" goal!